CPMP delivers positive opinion on Kaletra
On 14th December 2000, the Committee for Proprietary Medicinal Products (CPMP) adopted a positive opinion to recommend the granting of a marketing authorisation for the medicinal product Kaletra (133.3 mg lopinavir/33.3 mg ritonavir soft capsules and 80 mg lopinavir/20 mg ritonavir oral solution) intended for treatment of HIV-1 infection. The applicant for this medicinal product is Abbott Laboratories Limited. Marketing authorisation now needs to be granted by the European Commission. Kaletra is currently available in the UK prior to marketing on named patient basis only by individual physician request to Abbott Laboratories.